Bioequivalence and bioequivalency testing

American Journal of Pharmaceutical Education

Volumn 63, Issue 2, 1999, Pages 194-198

  Balthasar, Joseph P ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001161124     PISSN: 00029459     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9459(24)01740-6     Document Type: Article

References (13)

1. Food and Drug Administration - Center for Drug Evaluation and Research, Approved drug products with therapeutic equivalence evaluations, [may be accessed from: http://www.fda.gov/cder/orange/adp.htm], (1998).
2. Food and Drug Administration - Office of Generic Drugs - Division of Bioequivalence, Guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design [may be accessed from: http://www.fda.gov/cder/guidance/index.htm], (1992).
3. Schall, R. and Williams, R.L., "Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group," J. Pharmacokinet. Biopharm., 24, 133-149(1996).
4. Patnaik, R.N., Lesko, L.J., Chen, M.L. and Williams, R.L., "Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. PDA Individual Bioequivalence Working Group," Clin. Pharmacokinet., 33, 1-6(1997).
5. Basson, R.P., Cerimele, B.J., DeSante, K.A. and Howey, D.C., "Tmax: an unconfounded metric for rate of absorption in single dose bioequivalence studies," Pharm. Res., 13, 324-8(1996).
6. Lacey, L.F., Keene, O.N., Duquesnoy, C. and Bye, A., "Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies [see comments]," J. Pharm. Sci., 83, 212-215(1994).
7. Shand, D.G., Nuckolls, E.M. and Dates, J.A., "Plasma propranolol levels in adults with observations in four children," Clin. Pharmacol. Thier., 11, 112-120(1970).
8. Tsang, Y.C., Pop, R., Gordon, P., Hems, J. and Spino, M., "High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil," Pharm Res, 13, 846-850(1996).
9. Shah, V.P., Yacobi, A., Barr, W.H., Benet, L.Z., Breimer, D., Dobrinska, M.R., Endrenyi, L., Fairweather, W., Gillespie, W, Gonzalez, M.A., Hooper, J., Jackson, A., Lesko, L.J., Midha, K.K., Noonan, P.K., Patnaik, R. and Williams, R.L., "Evaluation of orally administered highly variable drugs and drug formulations," Pharm Res, 13, 1590-1594(1996).
10. Gibaldi, M. and Perrier, D., Pharmacokinetics, 2nd ed., Marcel Dekker, New York NY (1982)
11. D'Argenio, D.Z. and Schumitzky, A., ADAPT II User's Guide: Pharmacokinetic / Pharmacodynamic Systems Analysis Software, Release 4, Biomedical Simulations Resource, Los Angeles (1997).
12. Kovarik, J.M., Mueller, E.A., van Bree, J.B., Tetzloff, W. and Kutz, K., "Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation," J. Pharm. Sci., 83, 444-446(1994).
13. Food and Drug Administration - Center for Drug Evaluation and Research, In vivo bioequivalence studies based on population and individual bioequivalence approaches - Draft guidance [may be accessed from: http://www.fda.gov/cder/guidance/index.htm], (1997).